Rosemont Pharmaceuticals has acquired Lucis Pharma Ltd, a specialist pharmaceutical business in the UK
Acquired in June 2023, the Lucis acquisition brings accelerated growth opportunities for Rosemont through a broadened portfolio, with access to new attractive product areas and further pipeline products.
Founded in 2012, Lucis is a dedicated provider in the development and licensing of high-quality generic medicines, committed to improving healthcare accessibility and affordability. Our focus is on delivering effective and safe medications that meet rigorous standards.
This acquisition will enable Rosemont to broaden its portfolio and enter the unit dose / sachet market through the pipeline products, whilst growing the business through recent Lucis product launches in 2021/22.
Rosemont Pharmaceuticals has acquired Lucis Pharma Ltd, a specialist pharmaceutical business in the UK
Rosemont Pharmaceuticals has acquired Lucis Pharma Ltd, a specialist pharmaceutical business in the UK
Acquired in June 2023, the Lucis acquisition brings accelerated growth opportunities for Rosemont through a broadened portfolio, with access to new attractive product areas and further pipeline products.
Founded in 2012, Lucis is a dedicated provider in the development and licensing of high-quality generic medicines, committed to improving healthcare accessibility and affordability. Our focus is on delivering effective and safe medications that meet rigorous standards.
This acquisition will enable Rosemont to broaden its portfolio and enter the unit dose / sachet market through the pipeline products, whilst growing the business through recent Lucis product launches in 2021/22.
Rosemont Pharmaceuticals has acquired Lucis Pharma Ltd, a specialist pharmaceutical business in the UK
Acquired in June 2023, the Lucis acquisition brings accelerated growth opportunities for Rosemont through a broadened portfolio, with access to new attractive product areas and further pipeline products.
Founded in 2012, Lucis is a dedicated provider in the development and licensing of high-quality generic medicines, committed to improving healthcare accessibility and affordability. Our focus is on delivering effective and safe medications that meet rigorous standards.
This acquisition will enable Rosemont to broaden its portfolio and enter the unit dose / sachet market through the pipeline products, whilst growing the business through recent Lucis product launches in 2021/22.
Rosemont Pharmaceuticals has acquired Lucis Pharma Ltd, a specialist pharmaceutical business in the UK
Acquired in June 2023, the Lucis acquisition brings accelerated growth opportunities for Rosemont through a broadened portfolio, with access to new attractive product areas and further pipeline products.
Founded in 2012, Lucis is a dedicated provider in the development and licensing of high-quality generic medicines, committed to improving healthcare accessibility and affordability. Our focus is on delivering effective and safe medications that meet rigorous standards.
This acquisition will enable Rosemont to broaden its portfolio and enter the unit dose / sachet market through the pipeline products, whilst growing the business through recent Lucis product launches in 2021/22.
Rosemont Pharmaceuticals has acquired Lucis Pharma Ltd, a specialist pharmaceutical business in the UK
Acquired in June 2023, the Lucis acquisition brings accelerated growth opportunities for Rosemont through a broadened portfolio, with access to new attractive product areas and further pipeline products.
Founded in 2012, Lucis is a dedicated provider in the development and licensing of high-quality generic medicines, committed to improving healthcare accessibility and affordability. Our focus is on delivering effective and safe medications that meet rigorous standards.
This acquisition will enable Rosemont to broaden its portfolio and enter the unit dose / sachet market through the pipeline products, whilst growing the business through recent Lucis product launches in 2021/22.
Rosemont Pharmaceuticals has acquired Lucis Pharma Ltd, a specialist pharmaceutical business in the UK
Acquired in June 2023, the Lucis acquisition brings accelerated growth opportunities for Rosemont through a broadened portfolio, with access to new attractive product areas and further pipeline products.
Founded in 2012, Lucis is a dedicated provider in the development and licensing of high-quality generic medicines, committed to improving healthcare accessibility and affordability. Our focus is on delivering effective and safe medications that meet rigorous standards.
This acquisition will enable Rosemont to broaden its portfolio and enter the unit dose / sachet market through the pipeline products, whilst growing the business through recent Lucis product launches in 2021/22.
Rosemont Pharmaceuticals has acquired Lucis Pharma Ltd, a specialist pharmaceutical business in the UK
Acquired in June 2023, the Lucis acquisition brings accelerated growth opportunities for Rosemont through a broadened portfolio, with access to new attractive product areas and further pipeline products.
Founded in 2012, Lucis is a dedicated provider in the development and licensing of high-quality generic medicines, committed to improving healthcare accessibility and affordability. Our focus is on delivering effective and safe medications that meet rigorous standards.
This acquisition will enable Rosemont to broaden its portfolio and enter the unit dose / sachet market through the pipeline products, whilst growing the business through recent Lucis product launches in 2021/22.
Rosemont Pharmaceuticals has acquired Lucis Pharma Ltd, a specialist pharmaceutical business in the UK
Acquired in June 2023, the Lucis acquisition brings accelerated growth opportunities for Rosemont through a broadened portfolio, with access to new attractive product areas and further pipeline products.
Founded in 2012, Lucis is a dedicated provider in the development and licensing of high-quality generic medicines, committed to improving healthcare accessibility and affordability. Our focus is on delivering effective and safe medications that meet rigorous standards.
This acquisition will enable Rosemont to broaden its portfolio and enter the unit dose / sachet market through the pipeline products, whilst growing the business through recent Lucis product launches in 2021/22.